For additional inquiries, please contact the corresponding author.
Do not stop your medication without consulting your healthcare provider unless you experience symptoms suggesting serious adverse events like pancreatitis or severe allergic reaction
Marazzato F, McCarthy C, Field RH, Nguyen H, Nguyen T, Shepherd JA, et al
For example, the FDA-approved obesity dose for semaglutide is a 16-week step-up to a maintenance of 1.7 or 2.4 mg weekly
Additionally, GLP-1 RAs exhibit neuroprotective and anti-inflammatory effects, increase Akt dephosphorylation, decrease proinflammatory factors such as TNF-, elevate neurotrophic factors like BDNF, reduce oxidative stress and microglial activation, and enhance gut-brain axis function and gut microbiota stability [176]
Second, many effective tools are available to manage obesity, but they are not widely used, for a variety of reasons